Having trouble accessing articles? Reset your cache.

Relay’s protein motion platform approaches clinical starting line

The $520 million bet on Relay’s platform is slated to get its first clinical test in 2020

With its first program due to enter the clinic this year, Relay will test its hypothesis that characterizing full-length protein targets across a range of conformations leads to better therapeutic candidates than conventional structure-based drug design.

Investors have collectively bet $520 million on Relay Therapeutics Inc.’s approach, which is enabling the company to take multiple cancer programs to the clinic and

Read the full 614 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE